Answers are grounded in this paper and cite their sources.
Studies of the newer antiepileptic drugs suggest that they are exciting additions with improved efficacy and a perhaps decreased toxicity in certain types of refractory childhood epilepsy. In some very rare syndromes only anecdotal reports exist and further study is needed. Issues of tolerability, long-term safety in very young children, and effects on learning, behavior and other cognitive functions must be balanced with the possibility of improved efficacy. Additional well-controlled studies taking into account both seizure types and epilepsy syndromes are very much needed in neonates, infants, school aged children and adolescents.
No takes yet. Share an insight, caveat, or question.
John M. Pellock (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: